Drug Profile
Research programme: oral therapeutics - Global Blood Therapeutics
Alternative Names: GB 18713; GBT 018713; GBT 1118Latest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator Global Blood Therapeutics
- Class Small molecules
- Mechanism of Action Haemoglobin modulators; Kallikrein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hereditary angioedema; Hypoxia; Sickle cell anaemia
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Sickle-cell-anaemia in USA (PO)
- 05 Oct 2022 Global Blood Therapeutics has been acquired by Pfizer
- 05 Dec 2020 Pharmacodynamics data from preclinical studies in Sickle cell anaemia presented at the 62nd Annual Meeting and Exposition of the American Society of Haematology (ASH-2020)